Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia

Trial Profile

Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Aug 2018.
    • 13 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top